PT  - JOURNAL ARTICLE
AU  - Kuznar, Wayne
ED  - Rose, John
TI  - DECIDE
DP  - 2015 Jun 20
TA  - MD Conference Express
PG  - 19--19
VI  - 15
IP  - 9
4099  - http://mdc.sagepub.com/content/15/9/19.short
4100  - http://mdc.sagepub.com/content/15/9/19.full
AB  - The DECIDE study demonstrates that the humanized monoclonal antibody daclizumab high-yield process is superior to interferon beta-1a on brain magnetic resonance imaging measures of disease activity in patients with relapsing-remitting multiple sclerosis, supporting previous findings of a reduction in the annualized relapse rate.